Go to content
UR Home

Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID)

URN to cite this document:
DOI to cite this document:
Witt, M. ; Grunke, M. ; Proft, F. ; Bäuerle, M. ; Aringer, M. ; Burmester, G. ; Chehab, B. ; Fiehn, C. ; Fischer-Betz, R. ; Fleck, Martin
License: Allianz- bzw. Nationallizenz
PDF - Published Version
Date of publication of this fulltext: 26 Aug 2016 05:35


Objective The objective of this article is to evaluate the safety and clinical outcome of rituximab treatment in systemic lupus erythematosus (SLE) patients refractory to standard of care therapy in a real-life setting in Germany. Methods The GRAID registry included patients with different autoimmune diseases who were given off-label treatment with rituximab. Data on safety and clinical response ...


Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: datahub@ur.de
0941 943 -5707

Contact persons